Arca
Skip to content
Tools
Tools

Disialoganglioside GD2

Small molecule in Homo sapiens that 9 drugs act on.

  • Drugs that act on it: 9
  • Approved: 3
  • In phases 1 to 3: 6
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3
  • Other 6

Approved3

  • Dinutuximab
  • Dinutuximab beta
  • Naxitamab

Phase 31

Phase 23

  • 4B5
  • BIW-8962
  • EMD-273063

Phase 12

  • 14G2A
  • MORAB-028

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
DinutuximabBoxed warningApprovedUnited TherapeuticsAntibodyBinding agentDisialoganglioside GD2 binding agent28
Dinutuximab betaApprovedBeOne MedicinesAntibodyInhibitorDisialoganglioside GD2 inhibitor20
NaxitamabBoxed warningApprovedY-mAbs TherapeuticsAntibodyBinding agentDisialoganglioside GD2 binding agent17
ANTI-GD2 monoclonal antibody 3F8Phase 3Y-mAbs TherapeuticsOtherOtherDisialoganglioside GD2 other2
4B5Phase 2AstraZeneca PharmaceuticalsOtherOtherDisialoganglioside GD2 other5
BIW-8962Phase 2Kyowa KirinOtherInhibitorDisialoganglioside GD2 inhibitor0
EMD-273063Phase 2—OtherOtherDisialoganglioside GD2 other0
14G2APhase 1—OtherInhibitorDisialoganglioside GD2 inhibitor1
MORAB-028Phase 1MorphotekOtherCross-linking agentDisialoganglioside GD2 cross-linking agent0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaDinutuximab, Naxitamab, Dinutuximab betaPhase 2RecruitingGiselle ShollerNov 12, 2026
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Dinutuximab, Dinutuximab betaPhase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, FranceOct 1, 2026
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaDinutuximab, Dinutuximab betaPhase 1RecruitingChang Gung Memorial HospitalJul 7, 2026
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5NaxitamabPhase 2RecruitingShaare Zedek Medical CenterApr 17, 2026
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseDinutuximab, Dinutuximab betaPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Feb 27, 2026
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaDinutuximab, Dinutuximab betaPhase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyJan 29, 2026
A Multi-Arm, Platform Trial For Relapsed NeuroblastomaDinutuximab, Dinutuximab betaPhase 1 / Phase 2RecruitingUniversity of BirminghamJan 12, 2026
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in ChildrenDinutuximab, Dinutuximab betaPhase 2RecruitingTianjin Medical University Cancer Institute and HospitalJan 6, 2026
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabDinutuximabPhase 2Not yet recruitingNew Approaches to Neuroblastoma Therapy ConsortiumDec 3, 2025
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort4B5—RecruitingAstraZenecaAug 3, 2025
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaNaxitamabPhase 1RecruitingSteven DuBois, MDJun 18, 2025
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)NaxitamabPhase 1 / Phase 2RecruitingM.D. Anderson Cancer CenterJun 9, 2025
International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaDinutuximab betaPhase 1RecruitingProf. Dr. Dr. Birgit BurkhardtFeb 21, 2025
Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/54B5—Not yet recruitingCentre Hospitalier Universitaire de BesanconFeb 13, 2025
Adding Of Naxitamb In Induction Therapy For High Risk NeuroblastomaNaxitamab—RecruitingGuangzhou Women and Children's Medical CenterAug 28, 2024
Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaNaxitamabPhase 2RecruitingGiselle ShollerAug 7, 2024
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaNaxitamabPhase 2RecruitingMemorial Sloan Kettering Cancer CenterJul 30, 2024
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer4B5—RecruitingBlokhin's Russian Cancer Research CenterJun 10, 2024
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer4B5Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Feb 12, 2024
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.NaxitamabPhase 4Not yet recruitingSciClone PharmaceuticalsSep 21, 2023
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast CancerANTI-GD2 monoclonal antibody 3F8Phase 1 / Phase 2RecruitingMargaret Gatti-MaysSep 7, 2023
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)14G2APhase 1RecruitingStanford UniversityDec 12, 2019
The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer4B5Not applicableRecruitingSaint Vincent's Hospital, KoreaSep 30, 2016
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaANTI-GD2 monoclonal antibody 3F8Phase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterJul 20, 2015

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390823, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.